Avita Taps Sinopharm To Ramp-Up China Sales Of ReCell "Spray-On-Skin"
Executive Summary
Avita Medical has awarded Sinopharm with exclusive rights to distribute across China ReCell, an autologous cell harvesting device that creates a cellular suspension made from the patient’s own skin for use in advanced wound care and the treatment of skin defects. This "spray-on-skin" can be used in conjunction with all other key wound care approaches and is currently in a multi-center pivotal trial to obtain US FDA premarket approval, which is expected in Q3 2017.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.